Is there an Indian version of Ripretinib?

Ripretinib is an oral switch-controlled tyrosine kinase inhibitor. Its broad activity has been further confirmed in mouse models, including exon 17 resistance and gastrointestinal stromal tumor patient-derived xenograft models. It was developed specifically for primary and secondary KIT and PDGFRα resistance mutations. There is currently no Indian version of Ripretinib produced and marketed overseas.

Switch kinase inhibitors are a new class of innovative drugs. Repectinib is a Type II switch-controlled TKI with a complex mechanism of action. It can certain elements of the inhibitor structure antagonize the activation loop switch occupying the KIT-type active conformation, and other elements of the inhibitor stabilize the activation loop switch of the Type II inactive conformation. Furthermore, in the absence of exon 11 mutations, repectinib occupies the inhibitory pocket occupied by the juxtamembrane domain. In in vitro and cell-based studies, repetitinib demonstrated significant inhibitory activity against proto-oncogene kinase receptorsPDGFRB, TIE2, VEGFR2 and BRAF.

The original drug of Ripetinib has been marketed in China and has been approved by the National Medical Insurance Bureau to enter the scope of Class B medical insurance, but it is limited to patients who meet the indications. The price of each box of 50mg*30 tablets may be around 30,000 yuan. The expensive price may increase the pressure on families with heavy financial burdens. The US version of Ripetinib Specifications50mg*90 tablets sold overseas may be priced around RMB 77,000 per box (the price may fluctuate due to exchange rates). The ingredients of foreign original drugs are basically the same as those of domestic original drugs. For specific prices and drug information, please consult Yaode’s medical consultant.